TGFΒ1-induced inflammation in premalignant epidermal squamous lesions requires IL-17

Journal of Investigative Dermatology

Volumn 130, Issue 9, 2010, Pages 2295-2303

  Mohammed, Javed ^a   Ryscavage, Andrew ^b   Perez Lorenzo, Rolando ^a   Gunderson, Andrew J ^a   Blazanin, Nicholas ^a   Glick, Adam B ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; MYELOPEROXIDASE; TRANSFORMING GROWTH FACTOR BETA1; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EPIDERMIS; GAMMA DELTA T LYMPHOCYTE; KERATINOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; SKIN PAPILLOMA; SKIN TUMOR; T LYMPHOCYTE; TH17 CELL; TUMOR REGRESSION; ANIMAL; CELL CULTURE; DERMATITIS; DISEASE COURSE; DNA MICROARRAY; GENETICS; IMMUNOLOGY; METABOLISM; PAPILLOMA; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DERMATITIS; DISEASE PROGRESSION; EPIDERMIS; INTERLEUKIN-17; KERATINOCYTES; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMA; PRECANCEROUS CONDITIONS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77955712087     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.92     Document Type: Article

References (50)

1. Bae DS, Blazanin N, Licata M et al. (2009) Tumor suppressor and oncogene actions of TGFbeta1 occur early in skin carcinogenesis and are mediated by Smad3. Mol Carcinog 48:441-453
2. Benchetrit F, Ciree A, Vives V et al. (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99:2114-2121
3. Bettelli E, Carrier Y, Gao W et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238
4. Darwiche N, Ryscavage A, Perez-Lorenzo R et al. (2007) Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion. Oncogene 26:6885-6895
5. de Caestecker MP, Piek E, Roberts AB (2000) Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92:1388-1402
6. Dlugosz AA, Cheng C, Williams EK et al. (1994) Alterations in murine keratinocyte differentiation induced by activated rasHa genes are mediated by protein kinase C-alpha. Cancer Res 54:6413-6420
7. Fitch EL, Rizzo HL, Kurtz SE et al. (2009) Inflammatory skin disease in K5.hTGF-beta1 transgenic mice is not dependent on the IL-23/Th17 inflammatory pathway. J Invest Dermatol 129:2443-2450
8. Fridlender ZG, Sun J, Kim S et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16:183-194
9. Girardi M (2006) Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol 126:25-31
10. Glick AB (2004) TGFbeta1, back to the future: revisiting its role as a transforming growth factor. Cancer Biol Ther 3:276-283
11. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118-1122
12. 1 associates with disease progression in human breast cancer. Cancer Res 52:6949-6952
13. Hayday AC (2009) Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 31:184-196
14. Hennings H, Glick AB, Lowry DT et al. (1993) FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 14:2353-2358
15. HogenEsch H, Dunham A, Seymour R et al. (2006) Expression of chitinase-like proteins in the skin of chronic proliferative dermatitis (cpdm/cpdm) mice. Exp Dermatol 15:808-814
16. Ito Y, Usui T, Kobayashi S et al. (2009) Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum 60:2294-2303
17. Jovanovic DV, Di Battista JA, Martel-Pelletier J et al. (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:3513-3521
18. Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21:467-476
19. Krueger GG, Langley RG, Leonardi C et al. (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356:580-592
20. Kryczek I, Banerjee M, Cheng P et al. (2009a) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141-1149
21. Kryczek I, Wei S, Szeliga W et al. (2009b) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357-359
22. Kryczek I, Wei S, Zou L et al. (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178:6730-6733
23. Langowski JL, Zhang X, Wu L et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442:461-465
24. Letterio JJ, Roberts AB (1998) Regulation of immune responses by TGF-beta. Annu Rev Immunol 16:137-161
25. Li AG, Wang D, Feng XH et al. (2004) Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 23:1770-1781
26. Li MO, Wan YY, Sanjabi S et al. (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99-146
27. Liu X, Alexander V, Vijayachandra K et al. (2001) Conditional epidermal expression of TGFbeta 1 blocks neonatal lethality but causes a reversible hyperplasia and alopecia. Proc Natl Acad Sci USA 98:9139-9144
28. Lu SL, Reh D, Li AG et al. (2004) Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 64:4405-4410
29. Lugo-Villarino G, Maldonado-Lopez R, Possemato R et al. (2003) T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci USA 100:7749-7754
30. Mangan PR, Harrington LE, O'Quinn DB et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441:231-234
31. Martin-Orozco N, Muranski P, Chung Y et al. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787-798
32. Movahedi K, Guilliams M, Van den BJ et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233-4244
33. Muranski P, Boni A, Antony PA et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112:362-373
34. Muranski P, Restifo NP (2009) Does IL-17 promote tumor growth? Blood 114:231-232
35. Negoescu A, Lorimier P, Labat-Moleur F et al. (1996) In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem 44:959-968
36. Nograles KE, Zaba LC, Guttman-Yassky E et al. (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159:1092-1102
37. O'Brien RL, Roark CL, Born WK (2009) IL-17-producing gammadelta T cells. Eur J Immunol 39:662-666
38. Roark CL, Simonian PL, Fontenot AP et al. (2008) Gammadelta T cells: an important source of IL-17. Curr Opin Immunol 20:353-357
39. Roop DR, Lowy DR, Tambourin PE et al. (1986) An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 323:822-824
40. Shukla A, Ho Y, Liu X et al. (2008) Cripto-1 alters keratinocyte differentiation via blockade of transforming growth factor-beta1 signaling: role in skin carcinogenesis. Mol Cancer Res 6:509-516
41. Sullivan BM, Juedes A, Szabo SJ et al. (2003) Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci USA 100:15818-15823
42. Sutton CE, Lalor SJ, Sweeney CM et al. (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31:331-341
43. Tang B, Vu M, Booker T et al. (2003) TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112:1116-1124
44. Tian F, DaCosta BS, Parks WT et al. (2003) Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 63:8284-8292
45. Torre-Amione G, Beauchamp RD, Koeppen H et al. (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490
46. Veldhoen M, Hocking RJ, Atkins CJ et al. (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179-189
47. Wang L, Yi T, Kortylewski M et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206:1457-1464
48. Xiao M, Wang C, Zhang J et al. (2009) IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 69:2010-2017
49. Yang YA, Dukhanina O, Tang B et al. (2002) Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109:1607-1615
50. Youn JI, Nagaraj S, Collazo M et al. (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791-5802